B(effector)reaking bad in systemic sclerosis: role of a novel B cell subset.
作者信息
O'Reilly S, van Laar J
机构信息
Department of Biosciences, Durham University, Durham, UK.
Clinical Rheumatology Department, University Medical Centre Utrecht, Utrecht, the Netherlands.
出版信息
Clin Exp Immunol. 2020 Sep;201(3):231-232. doi: 10.1111/cei.13501.
Abstract
摘要
相似文献
1
B(effector)reaking bad in systemic sclerosis: role of a novel B cell subset.B（效应细胞）在系统性硬化症中“作恶”：一种新型B细胞亚群的作用
Clin Exp Immunol. 2020 Sep;201(3):231-232. doi: 10.1111/cei.13501.
2
B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis.在系统性硬化症的紧皮小鼠模型中，B淋巴细胞耗竭可减轻皮肤纤维化和自身免疫反应。
Am J Pathol. 2006 Sep;169(3):954-66. doi: 10.2353/ajpath.2006.060205.
3
The Th1/Th2 paradigm in the pathogenesis of scleroderma, and its modulation by thalidomide.硬皮病发病机制中的Th1/Th2模式及其受沙利度胺的调节。
Curr Rheumatol Rep. 2000 Dec;2(6):486-91. doi: 10.1007/s11926-000-0025-7.
4
Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma.托法替尼对博来霉素诱导的硬皮病小鼠模型的免疫调节作用。
J Dermatol Sci. 2021 Mar;101(3):174-184. doi: 10.1016/j.jdermsci.2020.12.007. Epub 2020 Dec 30.
5
Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis.系统性硬化症的发病机制：B细胞功能改变是连接系统性自身免疫和组织纤维化的关键。
J Dermatol Sci. 2005 Jul;39(1):1-7. doi: 10.1016/j.jdermsci.2005.03.013.
6
Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.利妥昔单抗治疗系统性硬化症。我们的经验和文献复习。
Autoimmun Rev. 2015 Nov;14(11):1072-8. doi: 10.1016/j.autrev.2015.07.008. Epub 2015 Jul 22.
7
Analysis of soluble and cell surface factors regulating anti-DNA topoisomerase I autoantibody production demonstrates synergy between Th1 and Th2 autoreactive T cells.调节抗DNA拓扑异构酶I自身抗体产生的可溶性和细胞表面因子分析表明，Th1和Th2自身反应性T细胞之间存在协同作用。
J Immunol. 2000 Jun 15;164(12):6138-46. doi: 10.4049/jimmunol.164.12.6138.
8
Semaphorin4A-Plexin D1 Axis Induces Th2 and Th17 While Represses Th1 Skewing in an Autocrine Manner.信号素 4A-丛蛋白 D1 轴以自分泌方式诱导 Th2 和 Th17，同时抑制 Th1 偏向。
Int J Mol Sci. 2020 Sep 22;21(18):6965. doi: 10.3390/ijms21186965.
9
[B cell abnormalities and therapeutic strategies in systemic sclerosis].[系统性硬化症中的B细胞异常与治疗策略]
Nihon Rinsho Meneki Gakkai Kaishi. 2016;39(3):197-206. doi: 10.2177/jsci.39.197.
10
Systemic sclerosis: New evidence re-enforces the role of B cells.系统性硬化症：新证据强化了 B 细胞的作用。
Autoimmun Rev. 2016 Feb;15(2):155-61. doi: 10.1016/j.autrev.2015.10.005. Epub 2015 Oct 21.
引用本文的文献
1
Esophageal Dysfunction in Systemic Sclerosis: An Update.系统性硬化症中的食管功能障碍：最新进展
Rheumatol Ther. 2021 Dec;8(4):1535-1549. doi: 10.1007/s40744-021-00382-0. Epub 2021 Oct 9.
本文引用的文献
1
Current and Potential New Targets in Systemic Sclerosis Therapy: a New Hope.系统性硬化症治疗的当前和潜在新靶点：新希望。
Curr Rheumatol Rep. 2020 Jun 19;22(8):42. doi: 10.1007/s11926-020-00918-3.
2
Generation of a novel CD30 B cell subset producing GM-CSF and its possible link to the pathogenesis of systemic sclerosis.生成一种新型的产生 GM-CSF 的 CD30+B 细胞亚群，及其与系统性硬化症发病机制的可能联系。
Clin Exp Immunol. 2020 Sep;201(3):233-243. doi: 10.1111/cei.13477. Epub 2020 Jul 14.
3
Toll-like receptors in mediating pathogenesis in systemic sclerosis.Toll 样受体在系统性硬化症发病机制中的作用。
Clin Exp Immunol. 2020 Jul;201(1):14-24. doi: 10.1111/cei.13426. Epub 2020 Feb 21.
4
Novel insights into dendritic cells in the pathogenesis of systemic sclerosis.树突状细胞在系统性硬化症发病机制中的新认识。
Clin Exp Immunol. 2020 Jul;201(1):25-33. doi: 10.1111/cei.13417. Epub 2020 Feb 13.
5
Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.利妥昔单抗治疗比环磷酰胺治疗更有效用于日本抗拓扑异构酶 I 阳性系统性硬皮病相关间质性肺病患者。
J Dermatol. 2019 Nov;46(11):1006-1013. doi: 10.1111/1346-8138.15079. Epub 2019 Sep 9.
6
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.托法替布治疗对 TNF 抑制剂应答不足的银屑病关节炎患者。
N Engl J Med. 2017 Oct 19;377(16):1525-1536. doi: 10.1056/NEJMoa1615977.
7
JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment.JAK1 依赖性 JAK2 转磷酸化限制了选择性 JAK2 抑制剂在长期治疗中的抗纤维化作用。
Ann Rheum Dis. 2017 Aug;76(8):1467-1475. doi: 10.1136/annrheumdis-2016-210911. Epub 2017 May 6.
8
Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity.系统性硬化症患者中调节性B细胞水平降低：与自身抗体产生及疾病活动的关联
Rheumatology (Oxford). 2016 Feb;55(2):263-7. doi: 10.1093/rheumatology/kev331. Epub 2015 Sep 8.
9
Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis.B 细胞耗竭疗法对弥漫性系统性硬化症肺部和皮肤受累的长期疗效。
Semin Arthritis Rheum. 2015 Feb;44(4):428-36. doi: 10.1016/j.semarthrit.2014.09.002. Epub 2014 Sep 8.
10
Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-β (TGF-β) signaling promoting SMAD3 activation and fibrosis via Gremlin protein.白细胞介素-6（IL-6）转信号驱动 STAT3 依赖性途径，导致过度活跃的转化生长因子-β（TGF-β）信号通过 Gremlin 蛋白促进 SMAD3 激活和纤维化。
J Biol Chem. 2014 Apr 4;289(14):9952-60. doi: 10.1074/jbc.M113.545822. Epub 2014 Feb 18.
Zotero 插件